Three Months of CAPOX Acceptable in High-Risk Stage II Colon Cancer

Five-year disease-free survival was noninferior for 3 versus 6 months of CAPOX therapy, but not for 3 versus 6 months of FOLFOX therapy.

The International Duration of Adjuvant Chemotherapy (IDEA) collaboration, which compared 3 versus 6 months of adjuvant chemotherapy in nearly 13,000 patients with stage III colon cancer, established 3 months of capecitabine and oxaliplatin (CAPOX) as the preferred treatment for nearly all patients (NEJM JW Oncol Hematol 2021 Feb and Lancet Oncol 2020; 21:1620). Investigators now report results for patients with high-risk stage II colon cancer included in four of the six IDEA trials.

Of nearly 3300 patients, 64.9% had vascular, lymphatic, or perineural invasion; 33.1% had T4 disease; 19.0% had inadequate nodal harvest; 16.1% had primary tumor obstruction; and 12.3% had perforation. Most patients (62%) received CAPOX, and 38% received fluorour…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Three Months of CAPOX Acceptable in High-Risk Stage II Colon Cancer

Topics

Reviewing Author